NeuroCog Trials, Inc. announces that Richard Keefe, Ph.D., Founder and CEO of NeuroCog Trials, was a featured speaker at the Autumn Conference of the International Society for CNS Clinical Trials and Methodology (ISCTM). Dr. Keefe’s presentation ‘Real-World Application of the MATRICS Consensus Cognitive Battery in Multisite Clinical Trials’ was an element of the session ‘ MATRICS Update and Beyond’.

Dr. Keefe said “The initial validation studies of the state of the art MATRICS Cognitive Consensus Battery (MCCB), completed during the MATRICS contract with NIMH, clearly demonstrated its test-retest reliability, small practice effects, correlations with measures of functional capacity, practicality and tolerability. However, it has been an empirical question whether the MCCB would demonstrate these favorable characteristics when administered in the context of a large multi-site industry trial for which it was designed.”

Dr. Keefe reviewed seven recent schizophrenia cognition trials that used the MCCB as a primary outcome measure and followed MATRICS study design guidelines. Results demonstrated excellent test-retest reliabilities, low missing data rates, small practice effects and excellent sensitivities to cognitive impairment. Dr. Keefe emphasized that “these studies included two international trials using non-English translations of the MCCB, over 1100 patients in all. The results from these separate trials suggest that the MCCB is a robust measure of cognition in schizophrenia for multisite clinical trials.”

Read more.